Brief: Congruence And Ono Pharma Expand Multi-Target Research Partnership
02/03/2026 23:26
March 2 (Reuters) - Ono Pharmaceutical Co Ltd 4528.T: CONGRUENCE AND ONO PHARMA EXPAND MULTI-TARGET RESEARCH PARTNERSHIP WITH THE ADDITION OF TWO NEW PROGRAMS ONO PHARMACEUTICAL CO - CONGRUENCE TO RECEIVE UNDISCLOSED UPFRONT PAYMENT, RESEARCH AND DEVELOPMENT FUNDING, MILESTONES AND ROYALTIES Source text: ID:nPn8J6TL7a Further company coverage: 4528.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ONO PHARMACEUTICAL
See all newsBrief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
Bristol Myers sues Amgen over proposed Opdivo biosimilar (updated)
Bristol Myers sues Amgen over proposed Opdivo biosimilar
Brief: UK's MHRA Says Vimseltinib Approved For Use In Adults To Treat Tenosynovial Giant Cell Tumours